Explore 3 Stock Ideas & Industry Insights Download Free Report

Galecto Inc

Company price
None USD 0.00(0%)
Last update at 2026-06-11T22:02:16.531036Z
Market Cap
1728.29M

Momentum Score

…

Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.45
Low
38.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-109.49%
Net Debt
-256.21M
ROCE
-15.20%
Diluted EPS TTM
-12.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -209.79M -21.40M -38.35M -61.62M -51.75M
Net income -209.84M -21.44M -38.35M -62.04M -51.28M
Selling general administrative 9.69M 10.50M 12.69M 13.00M 13.74M
Selling and marketing expenses - - 0.83M - -
Gross profit -174.31M -4.39M -0.83M - -
Reconciled depreciation 0.03M 0.18M 0.77M 0.49M 0.44M
Ebit -36.56M -21.29M -36.46M -61.21M -52.23M
Ebitda -36.53M -21.11M -35.63M -59.58M -52.10M
Depreciation and amortization 0.03M 0.18M 0.83M 1.63M 0.12M
Non operating income net other - - - -1.40M -
Operating income -36.56M -22.26M -39.91M -61.21M -52.23M
Other operating expenses 36.56M 22.26M 39.91M 61.21M 52.23M
Interest expense - - - 0.42M 0.47M
Tax provision 0.05M 0.04M 0.00M - -
Interest income 1.17M 0.84M 1.63M 0.72M 0.16M
Net interest income 1.17M 0.84M 1.63M 0.72M 0.16M
Income tax expense 0.05M 0.04M - 0.42M -0.47M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 36.56M 22.26M 39.91M 61.21M 52.23M
Cost of revenue 174.31M 4.39M 0.83M - -
Total other income expense net -173.23M 0.86M 1.56M -0.42M 0.47M
Net income from continuing ops -209.84M -21.44M -45.94M -61.88M -51.75M
Net income applicable to common shares - - - -61.62M -51.75M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 260.53M 17.13M 38.23M 73.19M 122.22M
Other current assets 1.90M 1.78M 1.90M 0.05M 0.33M
Total liab 20.15M 1.30M 5.90M 11.44M 4.99M
Total stockholder equity 240.38M 15.83M 32.33M 61.75M 117.22M
Other current liab 19.61M 0.81M 3.94M 7.28M 0.44M
Capital stock 416.25M 1.36M 0.00M 0.00M 0.00M
Retained earnings -487.36M -277.52M -256.08M -217.74M -156.11M
Other assets - - 0.00M 2.28M 2.03M
Cash 257.62M 14.18M 21.46M 32.79M 62.56M
Total current liabilities 20.07M 1.20M 5.83M 11.11M 4.54M
Current deferred revenue - - - - 2.18M
Net debt -256.21M -14.10M -21.22M -31.98M -61.72M
Short term debt 0.01M 0.01M 0.18M 0.48M 0.40M
Short long term debt total 1.41M 0.07M 0.25M 0.80M 0.85M
Other stockholder equity 310.69M 291.90M 288.04M 279.73M 273.65M
Property plant equipment - - - 0.36M 1.04M
Total current assets 260.42M 16.84M 36.77M 63.91M 110.10M
Long term investments - - 0.00M 5.83M 9.05M
Net tangible assets - - - 61.75M 117.22M
Short term investments - 0.00M 11.69M 27.44M 37.63M
Net receivables 0.90M 0.88M 1.72M 1.38M 2.28M
Inventory - - 0.00M 2.25M 7.30M
Accounts payable 0.44M 0.38M 1.70M 3.35M 1.53M
Accumulated other comprehensive income 0.80M 0.10M 0.38M -0.24M -0.32M
Retained earnings total equity - - - -217.74M -
Non currrent assets other 0.04M 0.16M 1.13M 2.28M 2.03M
Non current assets total 0.10M 0.29M 1.45M 9.28M 12.11M
Capital lease obligations 0.07M 0.07M 0.25M 0.80M 0.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 11.65M 27.08M 12.58M -48.05M
Change to liabilities - - - 6.49M -1.32M
Total cashflows from investing activities -17.37M 11.65M 22.33M 12.38M -48.05M
Total cash from financing activities 266.84M 0.00M 2.88M 0.51M 0.51M
Change to operating activities - - - 10.12M -5.30M
Net income -209.84M -21.44M -38.35M -61.62M -51.75M
Change in cash 243.45M -7.29M -11.32M -29.78M -101.27M
Begin period cash flow 14.18M 21.46M 32.79M 62.56M 163.84M
End period cash flow 257.62M 14.18M 21.46M 32.79M 62.56M
Total cash from operating activities -6.73M -18.62M -36.91M -42.93M -52.31M
Issuance of capital stock 266.81M 0.00M 2.94M 0.51M 0.00M
Depreciation 0.03M 0.18M 0.83M 0.49M 0.44M
Other cashflows from investing activities - - 0.08M - -
Sale purchase of stock - 1.89M - 0.51M -
Other cashflows from financing activities - - 22.33M 12.38M -48.05M
Change to netincome - - - 5.64M 5.63M
Capital expenditures 0.00M 0.00M 0.08M 0.20M 0.22M
Cash flows other operating - - - 5.96M -
Cash and cash equivalents changes - - - -30.04M -
Change in working capital 18.36M -2.67M -4.37M 11.94M -6.62M
Stock based compensation 1.00M 3.24M 5.43M 5.57M 4.48M
Other non cash items 183.72M 2.06M -0.45M 0.69M 0.07M
Free cash flow -6.73M -18.62M -36.91M -43.13M -52.53M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Galecto Inc

Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.

Ole Maaloes Vej 3, Copenhagen, Denmark, 2200

45 70 70 52 10

5

Name Title Year Born
Dr. Hans T. Schambye M.D., Ph.D. Co-Founder, Pres, CEO & Director 1966
Mr. Jonathan P. Freve CPA, CPA Chief Financial Officer 1978
Mr. Anders Pedersen Chief Operating Officer 1960
Mr. Ulf J. Nilsson Co-Founder NA
Dr. Hakon Leffler Co-Founder NA
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP Co-Founder & Member of the Clinical Advisory Board - IPF NA
Mr. Garrett Winslow Esq. Sr. VP, Gen. Counsel & Corp. Sec. 1979
Prof. Bertil Lindmark M.D., Ph.D. Chief Medical Officer 1955
Dr. Stephanie Oestreich Ph.D. Chief Bus. Officer 1974
Dr. Hans T. Schambye M.D., Ph.D. Co-Founder, President, CEO & Director 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…